Oribamide (Hydroxycarbamide)

Oribamide (hydroxycarbamide) is used in hematologic disorders that involve abnormal cell proliferation.

• Chronic myelogenous leukemia: helps control malignant proliferation of myeloid cells.
• Sickle cell disease: reduces frequency of painful crises and transfusion requirements.
• Polycythemia vera: lowers elevated red blood cell mass and helps manage disease symptoms.

• Hydroxycarbamide inhibits ribonucleotide reductase, the enzyme responsible for converting ribonucleotides to deoxyribonucleotides. This blockade reduces the intracellular pool of deoxyribonucleotides, limiting DNA synthesis and cell replication. The effect is most pronounced in rapidly dividing hematopoietic cells, thereby slowing the growth of malignant clones and modulating abnormal blood cell production.

Hydroxycarbamide may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea and vomiting: gastrointestinal upset occurring early in therapy.
• Fatigue: persistent tiredness that may affect daily activities.
• Skin hyperpigmentation: darkening of the skin, especially on the face and hands.
• Alopecia: temporary hair thinning or loss.
• Elevated liver enzymes: mild hepatic enzyme rise detectable on labs.

Serious or Rare Side Effects

• Myelosuppression: significant reduction in blood cell counts, increasing infection risk.
• Acute leukemic transformation: rare progression to a different leukemia subtype.
• Severe cutaneous reactions: such as Stevens‑Johnson syndrome.
• Renal toxicity: impaired kidney function in susceptible individuals.

When prescribing hydroxycarbamide, clinicians should consider several safety measures.

• Baseline monitoring: obtain complete blood count and liver function tests before initiation.
• Ongoing surveillance: regularly repeat hematologic and hepatic labs to detect toxicity early.
• Renal function: assess kidney status, especially in patients with pre‑existing impairment.
• Pregnancy and lactation: avoid use unless benefits clearly outweigh potential fetal or infant risks.
• Drug interactions: review concomitant medications for possible synergistic myelosuppression.
• Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Hydroxycarbamide can interact with other agents, altering efficacy or safety.

Major Interactions (Avoid)

• Anticoagulants (e.g., warfarin): increased bleeding risk due to additive bone‑marrow suppression.
• Other antimetabolites (e.g., methotrexate): heightened myelosuppression and organ toxicity.

Moderate Interactions (Monitor Closely)

• Allopurinol: may increase hydroxycarbamide plasma levels, requiring dose adjustment.
• NSAIDs: can exacerbate renal effects, especially in dehydrated patients.
• Live vaccines: reduced immune response, consider postponing vaccination.